Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Charles R. Romp, insider at Seagen

Charles R. Romp Insider Information

EVP of Seagen

Chip leads our U.S. commercial organization and has over 27 years of biotechnology and pharmaceutical experience. Since joining Seagen to build our original ADCETRIS sales team, he has consistently provided decisive leadership and clear direction, and fostered a team culture that is true to our patient-centric values. Chip has continued to deliver strong results with the expansion of our portfolio to three brands: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TUKYSA® (tucatinib). 

Previously, Chip was a National Sales Director for oncology and immunology products at Genentech, including Avastin® (bevacizumab) and Rituxan® (rituximab). While at Genentech, he also led deployment of the BioOncology sales forces. Earlier in his career, Chip was a Product Manager at GE Medical Systems and a pharmaceutical sales representative at Sankyo Park Davis and GlaxoSmithKline. 

Chip holds an M.B.A. from Saint Leo University (formerly Saint Leo College) and a B.A. from the University of Florida.  

What is Charles R. Romp's net worth?

The estimated net worth of Charles R. Romp is at least $8.83 million as of May 16th, 2022. Mr. Romp owns 49,483 shares of Seagen stock worth more than $8,831,231 as of June 29th. This net worth evaluation does not reflect any other assets that Mr. Romp may own. Additionally, Mr. Romp receives an annual salary of $1,020,000.00 as EVP at Seagen. Learn More about Charles R. Romp's net worth.

How old is Charles R. Romp?

Mr. Romp is currently 54 years old. There are 5 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer & Interim CEO, who is 66 years old. Learn More on Charles R. Romp's age.

What is Charles R. Romp's salary?

As the EVP of Seagen Inc., Mr. Romp earns $1,020,000.00 per year. There are 4 executives that earn more than Mr. Romp. The highest earning executive at Seagen is Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO, who commands a salary of $3,090,000.00 per year. Learn More on Charles R. Romp's salary.

How do I contact Charles R. Romp?

The corporate mailing address for Mr. Romp and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected] Learn More on Charles R. Romp's contact information.

Has Charles R. Romp been buying or selling shares of Seagen?

Charles R. Romp has not been actively trading shares of Seagen during the past quarter. Learn More on Charles R. Romp's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 42 times. They sold a total of 726,629 shares worth more than $115,625,220.08. The most recent insider tranaction occured on June, 17th when insider Vaughn B Himes sold 1,134 shares worth more than $181,440.00. Insiders at Seagen own 27.3 % of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 6/17/2022.

Charles R. Romp Insider Trading History at Seagen

See Full Table

Charles R. Romp Buying and Selling Activity at Seagen

This chart shows Charles R. Romp's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $178.47
Low: $175.61
High: $181.10

50 Day Range

MA: $142.08
Low: $108.81
High: $179.33

2 Week Range

Now: $178.47
Low: $105.43
High: $192.79


1,468,975 shs

Average Volume

1,249,163 shs

Market Capitalization

$32.85 billion

P/E Ratio


Dividend Yield



27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.